Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 16/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23234452 | 0.83 | DAO (0.41) | — | |
| SCHEMBL5786187 | 0.77 | SIRT2 (0.60) | PDE3BPDE3APDE2ATYRO3DYRK1B | |
| SCHEMBL1502964 | 0.77 | PDE3B (0.50) | PDE3BPDE3APDE2ATYRO3DYRK1B | |
| SCHEMBL16939766 | 0.76 | PDE3B (0.44) | PDE3BPDE3APDE2ATYRO3DYRK1B | |
| SCHEMBL1163700 | 0.76 | SIRT2 (0.64) | PDE3BPDE3APDE2ATYRO3DYRK1B | |
| SCHEMBL2419011 | 0.72 | PDE3B (0.47) | PDE3BPDE3APDE2ATYRO3DYRK1B | |
| SCHEMBL29703027 | 0.71 | PDE3B (0.41) | PDE3BPDE3APDE2ATYRO3DYRK1B | |
| SCHEMBL20777269 | 0.71 | ADORA3 (0.57) | PDE3BPDE3APDE2APRKD3MAP4K4 | |
| SCHEMBL29213685 | 0.71 | GALR3 (0.51) | PDE3BPDE3APDE2ATYRO3DYRK1B | |
| SCHEMBL11230300 | 0.70 | PDE3B (0.55) | PDE3BPDE3APDE2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021055591-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-09-27 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| EP-2485731-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044157-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDH2, CYP4B1, RB1 | PDE3B 901/4885PDE3A 928/4885PDE2A 1399/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PDE3B 3972/4885PDE3A 4057/4885PDE2A 4228/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PDE3B 3972/4885PDE3A 4057/4885PDE2A 4228/4885 |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | PDE3B 2625/4885PDE3A 2929/4885PDE2A 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.